FELINE Clinical Trial

New therapeutic trial in non-alcoholic fatty liver disease (NAFLD)

Centres are being sought to join this CLRN Portfolio Adopted Study. The NIHR EME scheme is supporting a new multicenter trial to examine whether the Angiotensin II Receptor Antagonist Losartan can slow or prevent liver fibrosis in patients with Non-Alcoholic Steatohepatitis (NASH).

Details can be found in the accompanying documents: